AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Phase 3positiveSKYRIZIPositive

AI Analysis

Summary

AbbVie presented Phase 3 AFFIRM data demonstrating that subcutaneous SKYRIZI (risankizumab-rzaa) achieved higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in patients with moderately to severely active Crohn's Disease, building on positive week 12 co-primary endpoint results.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Higher rates of endoscopic remission and ulcer-free endoscopy observed with subcutaneous SKYRIZI versus placebo. Results build on week 12 findings showing superiority in co-primary endpoints.

Importance:7/10

Sentiment:

0.80

Phase 3 dataCrohn's Diseaseendoscopic remissionsubcutaneous formulation

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on October 13, 2026 7:15 PM

Read Original